

# Elena Ranieri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4787492/publications.pdf>

Version: 2024-02-01

76  
papers

2,286  
citations

159585

30  
h-index

233421

45  
g-index

78  
all docs

78  
docs citations

78  
times ranked

3368  
citing authors

#	ARTICLE	IF	CITATIONS
1	mTOR inhibitors improve both humoral and cellular response to SARS-CoV-2 messenger RNA BNT16b2 vaccine in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 1475-1482.	4.7	42
2	Therapeutic Approach for Recurrent Focal Segmental Glomerulosclerosis in Pediatric Renal Transplant Recipients: A Single-Center Experience. <i>Blood Purification</i> , 2022, 51, 847-856.	1.8	2
3	Oxidative Stress and Ischemia/Reperfusion Injury in Kidney Transplantation: Focus on Ferroptosis, Mitophagy and New Antioxidants. <i>Antioxidants</i> , 2022, 11, 769.	5.1	32
4	CTL ELISPOT Assay and T Cell Detection. <i>Methods in Molecular Biology</i> , 2021, 2325, 65-77.	0.9	10
5	TLR-4 Signaling in Pericytes. <i>Pancreatic Islet Biology</i> , 2021, , 165-187.	0.3	0
6	mTOR inhibition improves mitochondria function/biogenesis and delays cardiovascular aging in kidney transplant recipients with chronic graft dysfunction. <i>Aging</i> , 2021, 13, 8026-8039.	3.1	9
7	Prospective Validation of Pentraxin-3 as a Novel Serum Biomarker to Predict the Risk of Prostate Cancer in Patients Scheduled for Prostate Biopsy. <i>Cancers</i> , 2021, 13, 1611.	3.7	16
8	Targeting Premature Renal Aging: from Molecular Mechanisms of Cellular Senescence to Senolytic Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 630419.	3.5	19
9	Pentraxin-3-mediated complement activation in a swine model of renal ischemia/reperfusion injury. <i>Aging</i> , 2021, 13, 10920-10933.	3.1	9
10	The Ambivalent Role of miRNAs in Carcinogenesis: Involvement in Renal Cell Carcinoma and Their Clinical Applications. <i>Pharmaceutics</i> , 2021, 14, 322.	3.8	10
11	Pathological diagnosis of Coronavirus-related nephropathy: insight from postmortem studies. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021, 58, 563-575.	6.1	1
12	The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review. <i>Cancers</i> , 2021, 13, 3949.	3.7	121
13	CD40 Cross-Linking Induces Migration of Renal Tumor Cell through Nuclear Factor of Activated T Cells (NFAT) Activation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8871.	4.1	3
14	Peripheral nervous system manifestations of Shiga toxin-producing E. coli-induced haemolytic uremic syndrome in children. <i>Italian Journal of Pediatrics</i> , 2021, 47, 181.	2.6	6
15	Role of Complement in Regulating Inflammation Processes in Renal and Prostate Cancers. <i>Cells</i> , 2021, 10, 2426.	4.1	13
16	Phenotypical and Functional Characterization of Cytotoxic Unconventional T-Cells. <i>Methods in Molecular Biology</i> , 2021, 2325, 29-39.	0.9	0
17	Protein-Bound Uremic Toxins and Immunity. <i>Methods in Molecular Biology</i> , 2021, 2325, 215-227.	0.9	10
18	Molecular Mechanisms of AKI in the Elderly: From Animal Models to Therapeutic Intervention. <i>Journal of Clinical Medicine</i> , 2020, 9, 2574.	2.4	17

#	ARTICLE	IF	CITATIONS
19	Modulation of complement activation by pentraxin-3 in prostate cancer. <i>Scientific Reports</i> , 2020, 10, 18400.	3.3	15
20	IgE-Mediated Immune Response and Antibody-Mediated Rejection. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1474-1483.	4.5	11
21	Altered Phosphorylation of Cytoskeleton Proteins in Peripheral Blood Mononuclear Cells Characterizes Chronic Antibody-Mediated Rejection in Kidney Transplantation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6509.	4.1	0
22	Recurrent Glomerulonephritis after Renal Transplantation: The Clinical Problem. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5954.	4.1	11
23	SARS-CoV-2 and Viral Sepsis: Immune Dysfunction and Implications in Kidney Failure. <i>Journal of Clinical Medicine</i> , 2020, 9, 4057.	2.4	31
24	The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?. <i>Frontiers in Immunology</i> , 2020, 11, 574271.	4.8	112
25	Low C3 Serum Levels Predict Severe Forms of STEC-HUS With Neurologic Involvement. <i>Frontiers in Medicine</i> , 2020, 7, 357.	2.6	12
26	PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma. <i>Aging</i> , 2020, 12, 7585-7602.	3.1	78
27	OUP accepted manuscript. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 450-460.	2.9	4
28	LPS removal reduces CD80-mediated albuminuria in critically ill patients with Gram-negative sepsis. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, F723-F731.	2.7	35
29	Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy. <i>Journal of Immunology Research</i> , 2019, 2019, 1-12.	2.2	9
30	Inflammation induces osteoclast differentiation from peripheral mononuclear cells in chronic kidney disease patients: crosstalk between the immune and bone systems. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 65-75.	0.7	41
31	Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUF4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. <i>Aging</i> , 2018, 10, 3957-3985.	3.1	133
32	Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 461.e15-461.e27.	1.6	75
33	TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours. <i>Molecular Cancer</i> , 2017, 16, 67.	19.2	73
34	Urinary RKIP/p-RKIP is a potential diagnostic and prognostic marker of clear cell renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 40412-40424.	1.8	50
35	miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction. <i>Journal of Translational Medicine</i> , 2016, 14, 84.	4.4	34
36	Establishment and characterization of a highly immunogenic human renal carcinoma cell line. <i>International Journal of Oncology</i> , 2016, 49, 457-470.	3.3	3

#	ARTICLE	IF	CITATIONS
37	Potential Salivary Proteomic Markers of Oral Squamous Cell Carcinoma. <i>Cancer Genomics and Proteomics</i> , 2016, 13, 55-61.	2.0	11
38	A type I interferon signature characterizes chronic antibody-mediated rejection in kidney transplantation. <i>Journal of Pathology</i> , 2015, 237, 72-84.	4.5	40
39	FP224THE ANALYSIS OF URINE UBIQUITINATED PROTEINS REVEALED IMPAIRED ACTIVATION OF COMPLEMENT AND COAGULATION CASCADES IN DIABETIC NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii141-iii142.	0.7	0
40	SP109PRELIMINARY EVALUATION OF UNCONVENTIONAL T CELLS IN RENAL CELL CARCINOMA (RCC) PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii413-iii413.	0.7	0
41	Soluble Serum $\beta$ -Klotho Is a Potential Predictive Marker of Disease Progression in Clear Cell Renal Cell Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e1917.	1.0	48
42	Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e2117.	1.0	45
43	FP053PKD1 AND PKD2 MUTATION ANALYSIS IN 90 UNRELATED ITALIAN PEDIGREES WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): SANGER SEQUENCING VS NEXT GENERATION SEQUENCING (NGS). <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii82-iii82.	0.7	0
44	Mechanisms of enhanced osteoclastogenesis in girls and young women with Turner's Syndrome. <i>Bone</i> , 2015, 81, 228-236.	2.9	31
45	Thrombin may modulate dendritic cell activation in kidney transplant recipients with delayed graft function. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1480-1487.	0.7	19
46	Two dimensional gel phosphoproteome of peripheral blood mononuclear cells: comparison between two enrichment methods. <i>Proteome Science</i> , 2014, 12, 46.	1.7	4
47	Pre-existing Type 2 Diabetes Mellitus Is an Independent Risk Factor for Mortality and Progression in Patients With Renal Cell Carcinoma. <i>Medicine (United States)</i> , 2014, 93, e183.	1.0	45
48	Rapamycin induces ILT3 <sup>high</sup> ILT4 <sup>high</sup> dendritic cells promoting a new immunoregulatory pathway. <i>Kidney International</i> , 2014, 85, 888-897.	5.2	48
49	Exposure to low- vs iso-osmolar contrast agents reduces NADPH-dependent reactive oxygen species generation in a cellular model of renal injury. <i>Free Radical Biology and Medicine</i> , 2014, 68, 35-42.	2.9	22
50	CTL ELISPOT Assay. <i>Methods in Molecular Biology</i> , 2014, 1186, 75-86.	0.9	34
51	Pentraxin 3: A Novel Biomarker for Predicting Progression from Prostatic Inflammation to Prostate Cancer. <i>Cancer Research</i> , 2014, 74, 4230-4238.	0.9	74
52	Negative and Positive Separation Techniques for the Isolation of Antigen-Specific CD8 <sup>+</sup> T Cells from Blood and Tumor Tissue. <i>Methods in Molecular Biology</i> , 2014, 1186, 1-11.	0.9	3
53	TRIM8 anti-proliferative action against chemo-resistant renal cell carcinoma. <i>Oncotarget</i> , 2014, 5, 7446-7457.	1.8	55
54	In Vitro Ex Vivo Generation of Cytotoxic T Lymphocytes. <i>Methods in Molecular Biology</i> , 2014, 1186, 13-20.	0.9	0



#	ARTICLE	IF	CITATIONS
73	Identification of GLA gene deletions in Fabry patients by Multiplex Ligation-dependent Probe Amplification (MLPA). <i>Molecular Genetics and Metabolism</i> , 2008, 94, 382-385.	1.1	36
74	Interferon-alpha (IFN- $\alpha$ )-conditioned DC Preferentially Stimulate Type-1 and Limit Treg-type In Vitro T-cell Responses From RCC Patients. <i>Journal of Immunotherapy</i> , 2008, 31, 254-262.	2.4	43
75	SVD Based Feature Selection and Sample Classification of Proteomic Data. <i>Lecture Notes in Computer Science</i> , 2008, , 556-563.	1.3	2
76	CD40L Proinflammatory and Profibrotic Effects on Proximal Tubular Epithelial Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 627-636.	6.1	37